Publications by authors named "Hyunjai Cho"

Background: Shortage of organ donors in the Republic of Korea has become a major problem. To address this, it has been questioned whether heart transplant (HTx) allocation should be modified to reduce priority of older patients. We aimed to evaluate post-HTx outcomes according to recipient age and specific pre-HTx conditions using a nationwide prospective cohort.

View Article and Find Full Text PDF

Background And Objectives: The Korean Organ Transplant Registry (KOTRY) provided data for this third official report on adult heart transplantation (HT), including information from 709 recipients.

Methods: Data from HTs performed at seven major centers in Korea between March 2014 and December 2020 were analyzed, focusing on immunosuppression, acute rejection, cardiac allograft vasculopathy (CAV), post-transplant survival, and mechanical circulatory support (MCS) usage.

Results: The median ages of the recipients and donors were 56.

View Article and Find Full Text PDF

Background: Latrophilin-2 (Lphn2), an adhesive GPCR (G protein-coupled receptor), was found to be a specific marker of cardiac progenitors during the differentiation of pluripotent stem cells into cardiomyocytes or during embryonic heart development in our previous studies. Its role in adult heart physiology, however, remains unclear.

Methods: The embryonic lethality resulting from deletion necessitates the establishment of cardiomyocyte-specific, tamoxifen-inducible knockout mice, which was achieved by crossing mice with mice having MerCreMer (tamoxifen-inducible Cre [Cyclization recombinase] recombinase) under the α-myosin heavy chain promoter.

View Article and Find Full Text PDF

Background: This comprehensive systematic review and meta-analysis investigated the mid- to long-term efficacy and safety of stem cell therapy in patients with acute myocardial infarction (AMI).

Methods: The study encompassed 79 randomized controlled trials with 7103 patients, rendering it the most up-to-date and extensive analysis in this field. This study specifically focused on the impact of stem cell therapy on left ventricular ejection fraction (LVEF), major adverse cardiac events (MACE), and infarct size.

View Article and Find Full Text PDF

Background: Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an under-recognized cause of heart failure (HF) with clinical phenotypes that vary across regions and genotypes. We sought to characterize the clinical characteristics of ATTR-CM in Asia.

Methods: Data from a nationwide cohort of patients with ATTR-CM from six major tertiary centres in South Korea were analysed between 2010 and 2021.

View Article and Find Full Text PDF

Unlabelled: With advancements in both pharmacologic and non-pharmacologic treatments, significant changes have occurred in heart failure (HF) management. The previous Korean HF registries, namely the Korea Heart Failure Registry (KorHF-registry) and Korean Acute Heart Failure Registry (KorAHF-registry), no longer accurately reflect contemporary acute heart failure (AHF) patients. Our objective is to assess contemporary AHF patients through a nationwide registry encompassing various aspects, such as clinical characteristics, management approaches, hospital course, and long-term outcomes of individuals hospitalized for AHF in Korea.

View Article and Find Full Text PDF

The effect of changes in immunosuppressive therapy during the acute phase post-heart transplantation (HTx) on clinical outcomes remains unclear. This study aimed to investigate the effects of changes in immunosuppressive therapy by corticosteroid (CS) weaning and everolimus (EVR) initiation during the first year post-HTx on clinical outcomes. We analyzed 622 recipients registered in the Korean Organ Transplant Registry (KOTRY) between January 2014 and December 2021.

View Article and Find Full Text PDF

Heart failure (HF) is a well-described final common pathway for a broad range of diseases however substantial confusion exists regarding how to describe, study, and track these underlying etiologic conditions. We describe (1) the overlap in HF etiologies, comorbidities, and case definitions as currently used in HF registries led or managed by members of the global HF roundtable; (2) strategies to improve the quality of evidence on etiologies and modifiable risk factors of HF in registries; and (3) opportunities to use clinical HF registries as a platform for public health surveillance, implementation research, and randomized registry trials to reduce the global burden of noncommunicable diseases. Investment and collaboration among countries to improve the quality of evidence in global HF registries could contribute to achieving global health targets to reduce noncommunicable diseases and overall improvements in population health.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the eligibility of heart failure patients for dapagliflozin and its cost-effectiveness compared to standard therapy, using data from the Korean Acute Heart Failure registry.
  • About 48.7% of the patients met eligibility criteria from previous clinical trials, with higher eligibility found in those with preserved ejection fraction.
  • Dapagliflozin was found to be cost-effective, especially for patients with a left ventricular ejection fraction of 40% or less, showing a significant benefit in quality-adjusted life years at a cost well below standard willingness-to-pay thresholds.
View Article and Find Full Text PDF
Article Synopsis
  • The FDA and EMA approved empagliflozin for reducing cardiovascular mortality and heart failure hospitalization in patients with HFrEF and HFpEF, but its real-world applicability is unclear.
  • A study analyzing data from the Korean Acute Heart Failure (KorAHF) registry found that 91.4% of patients met FDA/EMA criteria, while only 44.7% met trial criteria.
  • Empagliflozin was determined to be cost-effective at $6,764 per quality-adjusted life year (QALY), particularly for HFrEF patients ($5,012 per QALY), indicating potential benefits in clinical settings in South Korea.
View Article and Find Full Text PDF

Aims: Although the hypothesis that metformin is beneficial for patients with diabetes and heart failure (HF) has been steadily raised, there is limited data on metformin use in patients with acute HF. We analyzed the association of metformin on all-cause mortality in hospitalized patients with type 2 diabetes and acute HF.

Methods: The Korean Acute Heart Failure registry prospectively enrolled patients hospitalized for acute HF from 2011 to 2014.

View Article and Find Full Text PDF

Aims: Evidence for the effectiveness of left ventricular (LV) unloading in patients who received venoaterial extracorporeal membrane oxygenation (VA-ECMO) for acute myocardial infarction (AMI) or non-AMI induced cardiogenic shock (CS) is limited. The aim of the present study was to compare the effect of LV unloading in AMI-induced and non-AMI-induced CS.

Methods And Results: This is a single-centre retrospective observational study of patients with CS undergoing VA-ECMO from January 2011 to March 2019.

View Article and Find Full Text PDF

Background: Volume overload is associated not only with clinical manifestations but also with poor outcomes of heart failure (HF). However, there is an unmet need for effective methods for serial monitoring of volume status during HF hospitalization. The aim of this study was to evaluate the prognostic implication of serial measurement of bioelectrical impedance analysis (BIA) in patients hospitalized with acute HF.

View Article and Find Full Text PDF

The Korean Society of Heart Failure (KSHF) Guidelines provide evidence-based recommendations based on Korean and international data to guide adequate diagnosis and management of heart failure (HF). Since introduction of 2017 edition of the guidelines, management of advanced HF has considerably improved, especially with advances in mechanical circulatory support and devices. The current guidelines addressed these improvements.

View Article and Find Full Text PDF

Most patients with heart failure (HF) have multiple comorbidities, which impact their quality of life, aggravate HF, and increase mortality. Cardiovascular comorbidities include systemic and pulmonary hypertension, ischemic and valvular heart diseases, and atrial fibrillation. Non-cardiovascular comorbidities include diabetes mellitus (DM), chronic kidney and pulmonary diseases, iron deficiency and anemia, and sleep apnea.

View Article and Find Full Text PDF
Article Synopsis
  • The Korean Society of Heart Failure (KSHF) Guidelines offer evidence-based recommendations for diagnosing and managing heart failure, utilizing both Korean and international data.
  • The latest guidelines reflect significant advances in the treatment of advanced heart failure, particularly with mechanical circulatory support and devices since the 2017 edition.
  • Part IV of the guidelines focuses on the proper diagnosis and enhanced management strategies for both advanced and acute heart failure.
View Article and Find Full Text PDF
Article Synopsis
  • * Effective treatment for HF often includes a mix of medications like renin-angiotensin system inhibitors, diuretics, and anticoagulants based on specific conditions like atrial fibrillation or diabetes.
  • * Properly managing these comorbidities through medication and interventions like continuous positive airway pressure for sleep apnea is essential for better health outcomes in HF patients.
View Article and Find Full Text PDF

Lysophosphatidic acid receptor 4 (LPAR4) exhibits transient expression at the cardiac progenitor stage during pluripotent stem cell (PSC)-derived cardiac differentiation. Using RNA sequencing, promoter analyses, and a loss-of-function study in human PSCs, we discovered that SRY-box transcription factor 17 (SOX17) is an essential upstream factor of LPAR4 during cardiac differentiation. We conducted mouse embryo analyses to further verify our human PSC in vitro findings and confirmed the transient and sequential expression of SOX17 and LPAR4 during in vivo cardiac development.

View Article and Find Full Text PDF
Article Synopsis
  • - This study evaluates the effectiveness of a smartphone app designed to improve medication adherence in patients with atrial fibrillation (AF) who are prescribed non-vitamin K antagonist oral anticoagulants (NOACs), which is critical for stroke prevention.
  • - The RIVOX-AF trial will enroll 1,042 participants across 13 hospitals in South Korea, randomly assigning them to either the app-based intervention group or a control group to compare adherence levels over 24 weeks.
  • - Key outcomes being measured include adherence rates assessed by pill counts and clinical events such as strokes or major bleeding incidents during the follow-up period.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the effects of empagliflozin (EMPA) and sotagliflozin (SOTA) on heart failure and diabetes using a zebrafish model, revealing both drugs improve survival and cardiac function but differ in effectiveness at higher concentrations.
  • EMPA and SOTA were found to similarly inhibit sodium-hydrogen exchanger 1 (NHE1), suggesting this mechanism contributes to their cardioprotective effects.
  • However, at 25 μM concentration, SOTA resulted in poorer outcomes compared to EMPA, indicating that while both drugs have beneficial effects, EMPA may be the safer choice at higher doses.
View Article and Find Full Text PDF
Article Synopsis
  • The Korean Society of Heart Failure (KSHF) gives doctors advice on how to help patients with heart problems called heart failure (HF).
  • Since 2016, there have been new treatments for different types of heart failure, which makes the guidelines better and more updated.
  • This part of the guidelines focuses on ways to help patients with heart failure get better and live healthier lives.
View Article and Find Full Text PDF

The Korean Society of Heart Failure guidelines aim to provide physicians with evidence-based recommendations for diagnosing and managing patients with heart failure (HF). In Korea, the prevalence of HF has been rapidly increasing in the last 10 years. HF has recently been classified into HF with reduced ejection fraction (HFrEF), HF with mildly reduced ejection fraction (EF), and HF with preserved EF (HFpEF).

View Article and Find Full Text PDF
Article Synopsis
  • The Korean Society of Heart Failure (KSHF) created guidelines to help doctors treat patients with heart failure.
  • These guidelines were first made in 2016 and have been updated to include new treatments and research.
  • Part II of the guidelines focuses on strategies to make heart failure patients feel better and live longer.
View Article and Find Full Text PDF